10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
MERCK & CO., INC. | |||
Ticker: MRK Fiscal Year: 2014 | |||
Consolidated Statement of Cash Flows | |||
Period Ending Dec 31, 2014 10-K (Filed: Feb 27, 2015) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | |
| Cash Flows from Operating Activities | |||
| Net income | $ 11,934 | 4,517 | 6,299 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation and amortization | 6,691 | 6,988 | 6,978 |
| Intangible asset impairment charges | 1,222 | 765 | 200 |
| Gain on divestiture of Merck Consumer Care | (11,209) | 0 | 0 |
| Gain on AstraZeneca option exercise | (741) | 0 | 0 |
| Loss on extinguishment of debt | 628 | 0 | 0 |
| Equity income from affiliates | (257) | (404) | (642) |
| Dividends and distributions from equity method affiliates | 185 | 237 | 291 |
| Deferred income taxes | (2,600) | (330) | 669 |
| Share-based compensation | 278 | 276 | 335 |
| Other | (95) | 399 | 28 |
| Net changes in assets and liabilities: | |||
| Accounts receivable | (554) | 436 | 349 |
| Inventories | 79 | (365) | (482) |
| Trade accounts payable | 593 | 522 | (302) |
| Accrued and other current liabilities | 1,635 | (397) | (717) |
| Income taxes payable | (21) | (1,421) | (34) |
| Noncurrent liabilities | 190 | (132) | (1,747) |
| Other | (98) | 563 | (1,203) |
| Net Cash Provided by Operating Activities | 7,860 | 11,654 | 10,022 |
| Cash Flows from Investing Activities | |||
| Capital expenditures | (1,317) | (1,548) | (1,954) |
| Purchases of securities and other investments | (24,944) | (17,991) | (12,841) |
| Proceeds from sales of securities and other investments | 15,114 | 16,298 | 7,783 |
| Divestiture of Consumer Care business, net of cash divested | 13,951 | 0 | 0 |
| Dispositions of other businesses, net of cash divested | 1,169 | 46 | 0 |
| Proceeds from AstraZeneca option exercise | 419 | 0 | 0 |
| Acquisition of Idenix Pharmaceuticals, Inc., net of cash acquired | (3,700) | 0 | 0 |
| Acquisitions of other businesses, net of cash acquired | (181) | (246) | 0 |
| Acquisition of Bayer AG collaboration rights | (1,000) | 0 | 0 |
| Cash inflows from net investment hedges | 195 | 350 | 39 |
| Other | (80) | (57) | 168 |
| Net Cash Used in Investing Activities | (374) | (3,148) | (6,805) |
| Cash Flows from Financing Activities | |||
| Net change in short-term borrowings | (460) | (159) | 624 |
| Payments on debt | (6,617) | (1,775) | (22) |
| Proceeds from issuance of debt | 3,146 | 6,467 | 2,562 |
| Purchases of treasury stock | (7,703) | (6,516) | (2,591) |
| Dividends paid to stockholders | (5,170) | (5,157) | (5,116) |
| Other dividends paid | (77) | (120) | (120) |
| Proceeds from exercise of stock options | 1,560 | 1,210 | 1,310 |
| Other | 208 | 60 | 86 |
| Net Cash Used in Financing Activities | (15,113) | (5,990) | (3,267) |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | (553) | (346) | (30) |
| Net (Decrease) Increase in Cash and Cash Equivalents | (8,180) | 2,170 | (80) |
| Cash and Cash Equivalents at Beginning of Year | 15,621 | 13,451 | |
| Cash and Cash Equivalents at End of Year | 7,441 | 15,621 | 13,451 |
| External Links | |
| MERCK & CO., INC. (MRK) Fiscal Year 2014 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |